Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD [Phase 3]
This clinical trial update notes a Phase 3 study evaluating the safety and tolerability of L606 in patients with pulmonary arterial hyperten…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH) [NA]
Update on the RELIEVE-PAH trial evaluating a V-Wave device to reduce right ventricular failure in pulmonary arterial hypertension. The study…
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension [Phase 2]
This document reports the completion of a Phase 2 clinical trial evaluating the efficacy, safety and pharmacokinetics of treprostinil palmit…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome [Phase 2]
A Phase 2 clinical trial evaluating sotatercept in patients with congenital heart disease and Eisenmenger syndrome is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Mobile Health Intervention to Improve Exercise in Pediatric PH [NA]
A pediatric pulmonary arterial hypertension trial evaluating a mobile health intervention to improve exercise, currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Auto-immunity and Pulmonary Arterial Hypertension [NA]
Status update indicating a trial on auto-immunity and pulmonary arterial hypertension sponsored by Assistance Publique - Hôpitaux de Paris i…
-
FDA approval · 2026-03-25FDA Approved: WINREVAIR — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for WINREVAIR (sotatercept-CSRK) from Merck Sharp & Dohme LLC, updating the product labeling.
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Endothelial Cell Activation and Total Pulmonary Resistance in PAH [NA]
A clinical trial update from Imperial College London on endothelial cell activation and total pulmonary resistance in pulmonary arterial hyp…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.
This clinical trial update outlines an investigational longitudinal study to evaluate reverse remodeling of the pulmonary vasculature with S…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH) [Phase 3]
A Phase 3 study evaluating the efficacy and safety of once-daily Treprostinil Palmitil Inhalation Powder (TPIP) in participants with pulmona…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension [Phase 1]
A Phase 1 clinical trial is evaluating the efficacy and safety of empagliflozin for treatment of pulmonary arterial hypertension; the study …
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Validation of a Patient Knowledge Questionnaire for Pulmonary Hypertension [NA]
A clinical trial update on validating a Patient Knowledge Questionnaire for pulmonary hypertension is currently recruiting, sponsored by Uni…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) [Phase 1, Phase 2]
Ongoing Phase 1/2 study evaluating LTP001 in healthy volunteers and patients with pulmonary arterial hypertension, currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension? [NA]
The trial update indicates that AIRDROP is currently recruiting to study methods to improve adherence to inhaled therapy in pulmonary arteri…
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension [NA]
A clinical trial update examining the safety and impact of low resistance exercise training on quality of life in people with pulmonary arte…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Long-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial Hypertension
Clinical trial update on the long-term outcomes of selexipag for schistosomiasis-associated pulmonary arterial hypertension; the study statu…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: A Trial of "APL-9796'' in Adults With Pulmonary Hypertension [Phase 2]
Phase 2 clinical trial of APL-9796 for adults with pulmonary arterial hypertension is currently recruiting.
-
FDA approval · 2026-03-03FDA Approved: BOSENTAN — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Bosentan submitted by Zydus Pharmaceuticals USA Inc. under ANDA207760. The approval pertains to …
-
FDA approval · 2026-03-03FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for TRACLEER (bosentan) submitted by Actelion Pharmaceuticals US, Inc., resulting in changes to the …
-
FDA approval · 2026-03-03FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for TRACLEER (bosentan) submitted by Actelion Pharmaceuticals US, Inc.
-
FDA approval · 2026-03-03FDA Approved: BOSENTAN — Supplemental Application (Actavis Pharma, Inc.)
FDA approves a supplemental application for Bosentan by Actavis Pharma, Inc., allowing the referenced product to be marketed in its generic …
-
FDA approval · 2026-03-03FDA Approved: BOSENTAN — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for bosentan from Zydus Pharmaceuticals USA Inc., typically indicating a labeling or formulation…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH) [Phase 2]
Phase 2 clinical trial update for NS-863 in pulmonary arterial hypertension, currently not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
An expanded access study evaluating Treprostinil Palmitil Inhalation Powder (TPIP) for patients with pulmonary arterial hypertension and pul…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: 129 Xenon Imaging in Patients Treated With Sotatercept [Phase 2]
A Phase 2 clinical trial using Xenon imaging in patients treated with sotatercept for pulmonary hypertension is currently recruiting.